Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma by Carolyn Helms | Sep 16, 2024 | Portfolio News
Zenas BioPharma Announces Pricing of Upsized Initial Public Offering by Carolyn Helms | Sep 12, 2024 | Portfolio News
OrsoBio Announces Oversubscribed $67 Million Series B Financing to Accelerate Mitochondrial Protonophore Portfolio Targeting Obesity and Associated Disorders by Carolyn Helms | Sep 6, 2024 | Portfolio News
Opna Bio Doses First Patient in Phase 1 Study in Multiple Myeloma with OPN-6602, an EP300/CBP Bromodomain Inhibitor by Carolyn Helms | Aug 26, 2024 | Portfolio News
BioAge Appoints Former GSK CEO Jean-Pierre Garnier as Chair of Its Board of Directors by Carolyn Helms | Aug 22, 2024 | Portfolio News
